- Home
- CLNN vs IMA Comparison
CLNN vs IMA Comparison
Compare CLNN & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLNN | IMA |
|---|---|---|
| Founded | 2012 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.4M | 66.3M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CLNN | IMA |
|---|---|---|
| Price | $4.39 | $5.06 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 2 |
| Target Price | ★ $33.75 | $16.00 |
| AVG Volume (30 Days) | ★ 119.0K | 12.7K |
| Earning Date | 05-08-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $200,000.00 | ★ $800,000.00 |
| Revenue This Year | $17.64 | N/A |
| Revenue Next Year | $19,516.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.25 | $3.94 |
| 52 Week High | $13.50 | $9.10 |
Technical Indicators
Market Signals| Indicator | CLNN | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 53.74 | 48.48 |
| Support Level | $3.92 | $4.73 |
| Resistance Level | $4.70 | $6.13 |
| Average True Range (ATR) | 0.38 | 0.30 |
| MACD | 0.09 | 0.02 |
| Stochastic Oscillator | 96.64 | 56.79 |
Price Performance
Historical ComparisonAbout CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.